Workflow
RT产品线设备
icon
Search documents
联影医疗(688271):25Q3 收入增速亮眼,海外占比持续提升
Guoxin Securities· 2025-11-05 10:11
Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Views - The company reported significant revenue growth in Q3 2025, with a total revenue of 8.859 billion yuan, representing a year-on-year increase of 27.39%. The net profit attributable to shareholders reached 1.122 billion yuan, up 66.91% [1][2] - The domestic market is steadily recovering, with revenue of 6.866 billion yuan in the first three quarters of 2025, an increase of 23.7%. The overseas market showed remarkable growth, with revenue of 1.993 billion yuan, up 42.0%, increasing its revenue share to 22.5% [2] - The gross margin slightly decreased to 47.02%, down 2.40 percentage points, primarily due to price competition from centralized procurement. However, the company effectively controlled expenses, with significant reductions in sales, management, and R&D expense ratios [2] Summary by Sections Financial Performance - In Q3 2025, the company achieved a quarterly revenue of 2.843 billion yuan, a 75.41% increase year-on-year, and a net profit of 122 million yuan, up 143.80% [1] - For the first three quarters of 2025, equipment sales revenue was 7.071 billion yuan, a 23.7% increase, with specific product lines showing varied growth rates: CT (+8%), MR (+40%), MI (+22%), XR (+25%), and RT (+28%) [1] - The maintenance service business also grew rapidly, generating 1.243 billion yuan in revenue, a 28.4% increase, accounting for 14% of total revenue [1] Market Dynamics - The recovery in the domestic market is attributed to accelerated implementation of equipment update policies and a significant rebound in the bidding market [2] - The overseas market's revenue growth is notable, with a 42.0% increase, reflecting the company's successful expansion efforts [2] Profitability and Expense Management - The company's gross margin decreased slightly to 47.02%, influenced by price competition from centralized procurement [2] - The expense ratios showed improvement, with sales expense ratio at 17.19% (-2.73pp), management expense ratio at 5.05% (-0.87pp), and R&D expense ratio at 14.11% (-4.83pp) [2] Future Projections - The company maintains its profit forecast, expecting revenues of 12.41 billion yuan, 14.51 billion yuan, and 16.94 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 20.4%, 16.9%, and 16.8% [2] - The projected net profits for the same years are 1.95 billion yuan, 2.37 billion yuan, and 2.77 billion yuan, with growth rates of 54.5%, 21.7%, and 16.7% [2]